RNA therapeutics in the clinic

Area of Science:

• Molecular Biology
• Pharmacology
• Biotechnology

Background:

• Ribonucleic acid (RNA) therapeutics represent a significant advancement in medicine, gaining prominence due to their potential and the recent pandemic.
• Since the first RNA therapeutic approval in 1998, research has expanded to identify novel targets and enhance delivery systems for improved safety and efficacy.

Purpose of the Study:

• To provide a comprehensive overview of clinically relevant RNA therapeutics.
• To analyze the mechanisms of action and disease areas for approved and investigational RNA therapies.
• To identify challenges and propose strategies for the clinical translation of RNA therapeutics.

Main Methods:

• Review of 17 approved RNA therapeutics.
• In-depth analysis of 222 ongoing clinical trials involving RNA therapeutics.
• Examination of RNA therapeutic mechanisms, disease targets, and delivery strategies.

Main Results:

• The study details the current landscape of RNA therapeutics, including approved drugs and active clinical trials.
• Analysis reveals diverse mechanisms and a wide range of disease areas targeted by RNA-based interventions.
• Key challenges in clinical translation and potential solutions are highlighted.

Conclusions:

• RNA therapeutics are a rapidly evolving field with significant clinical progress and ongoing research.
• Continued innovation in delivery strategies and target identification is crucial for overcoming clinical translation hurdles.
• This overview provides valuable insights for researchers and clinicians navigating the development of RNA-based medicines.